A share price of Maravai LifeSciences Holdings Inc [MRVI] is currently trading at $1.93, up 9.04%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRVI shares have gain 9.04% over the last week, with a monthly amount drifted -14.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock has seen the most recent analyst activity on February 26, 2025, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $3 from $9. On December 05, 2024, downgrade downgraded it’s rating to Sell but maintained its price target of $4.25 on the stock. Wolfe Research started tracking the stock assigning a Peer Perform rating. William Blair downgraded its rating to a Mkt Perform. Wells Fargo started tracking with a Overweight rating for this stock on August 28, 2024, and assigned it a price target of $10. In a note dated August 13, 2024, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $11 to $10.
Maravai LifeSciences Holdings Inc experienced fluctuations in its stock price throughout the past year between $1.66 and $11.56. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] shares were valued at $1.93 at the most recent close of the market. An investor can expect a potential return of 159.07% based on the average MRVI price forecast.
Analyzing the MRVI fundamentals
Trailing Twelve Months sales for Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] were 259.19M which represents -23.92% decline. Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -0.9%, Pretax Profit Margin comes in at -1.01%, and Net Profit Margin reading is -0.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.38 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8067 points at the first support level, and at 1.6833 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0167, and for the 2nd resistance point, it is at 2.1033.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] is 7.53. As well, the Quick Ratio is 6.65, while the Cash Ratio is 5.66. Considering the valuation of this stock, the price to sales ratio is 1.90, the price to book ratio is 0.84.
Transactions by insiders
Recent insider trading involved ORESHACK KURT, General Counsel, that happened on Jan 31 ’25 when 25000.0 shares were sold. Officer, ORESHACK KURT completed a deal on Jan 31 ’25 to buy 25000.0 shares. Meanwhile, Director DeFord John A bought 17500.0 shares on Nov 12 ’24.
